Cargando…

Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid

MRONJ (Medication-Related Osteonecrosis of the Jaw) is a condition observed in a subset of cancer patients who have undergone treatment with zoledronic acid in order to either prevent or treat bone metastases. The primary aim of this research was to establish the importance of risk factors in the de...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciobanu, George Adrian, Camen, Adrian, Ionescu, Mihaela, Vlad, Daniel, Munteanu, Cristina Maria, Gheorghiță, Mircea Ionuț, Lungulescu, Cristian Virgil, Staicu, Ionela Elisabeta, Sin, Elena Claudia, Chivu, Luminița, Mercuț, Răzvan, Popescu, Sanda Mihaela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253558/
https://www.ncbi.nlm.nih.gov/pubmed/37297941
http://dx.doi.org/10.3390/jcm12113747
_version_ 1785056434746032128
author Ciobanu, George Adrian
Camen, Adrian
Ionescu, Mihaela
Vlad, Daniel
Munteanu, Cristina Maria
Gheorghiță, Mircea Ionuț
Lungulescu, Cristian Virgil
Staicu, Ionela Elisabeta
Sin, Elena Claudia
Chivu, Luminița
Mercuț, Răzvan
Popescu, Sanda Mihaela
author_facet Ciobanu, George Adrian
Camen, Adrian
Ionescu, Mihaela
Vlad, Daniel
Munteanu, Cristina Maria
Gheorghiță, Mircea Ionuț
Lungulescu, Cristian Virgil
Staicu, Ionela Elisabeta
Sin, Elena Claudia
Chivu, Luminița
Mercuț, Răzvan
Popescu, Sanda Mihaela
author_sort Ciobanu, George Adrian
collection PubMed
description MRONJ (Medication-Related Osteonecrosis of the Jaw) is a condition observed in a subset of cancer patients who have undergone treatment with zoledronic acid in order to either prevent or treat bone metastases. The primary aim of this research was to establish the importance of risk factors in the development of medication-related osteonecrosis of the jaw in cancer patients receiving zoledronic acid therapy for bone metastases. The present study is an observational retrospective investigation conducted at two university centers, namely, Craiova and Constanța, and included cancer patients treated with zoledronic acid. The medical records of the patients were obtained over a four-year timeframe spanning from June 2018 to June 2022. The data analysis was carried out between January 2021 and October 2022. Patients were treated for cancer, bone metastases, and MRONJ according to the international guidelines. The research investigated a cohort of 174 cancer patients (109 females and 65 males) aged between 22 and 84 years (with a mean age 64.65 ± 10.72 years) seeking treatment at oncology clinics situated in Craiova and Constanța. The study conducted a binomial logistic regression to analyze ten predictor variables, namely, gender, age, smoking status, treatment duration, chemotherapy, radiotherapy, endocrine therapy, presence of diabetes mellitus (DM), obesity, and hypertension (HT). The results of the analysis revealed that only five of the ten predictor variables were statistically significant for MRONJ occurrence: duration of treatment (p < 0.005), chemotherapy (p = 0.007), and hypertension (p = 0.002) as risk factors, and endocrine therapy (p = 0.001) and obesity (p = 0.024) as protective factors.
format Online
Article
Text
id pubmed-10253558
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-102535582023-06-10 Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid Ciobanu, George Adrian Camen, Adrian Ionescu, Mihaela Vlad, Daniel Munteanu, Cristina Maria Gheorghiță, Mircea Ionuț Lungulescu, Cristian Virgil Staicu, Ionela Elisabeta Sin, Elena Claudia Chivu, Luminița Mercuț, Răzvan Popescu, Sanda Mihaela J Clin Med Article MRONJ (Medication-Related Osteonecrosis of the Jaw) is a condition observed in a subset of cancer patients who have undergone treatment with zoledronic acid in order to either prevent or treat bone metastases. The primary aim of this research was to establish the importance of risk factors in the development of medication-related osteonecrosis of the jaw in cancer patients receiving zoledronic acid therapy for bone metastases. The present study is an observational retrospective investigation conducted at two university centers, namely, Craiova and Constanța, and included cancer patients treated with zoledronic acid. The medical records of the patients were obtained over a four-year timeframe spanning from June 2018 to June 2022. The data analysis was carried out between January 2021 and October 2022. Patients were treated for cancer, bone metastases, and MRONJ according to the international guidelines. The research investigated a cohort of 174 cancer patients (109 females and 65 males) aged between 22 and 84 years (with a mean age 64.65 ± 10.72 years) seeking treatment at oncology clinics situated in Craiova and Constanța. The study conducted a binomial logistic regression to analyze ten predictor variables, namely, gender, age, smoking status, treatment duration, chemotherapy, radiotherapy, endocrine therapy, presence of diabetes mellitus (DM), obesity, and hypertension (HT). The results of the analysis revealed that only five of the ten predictor variables were statistically significant for MRONJ occurrence: duration of treatment (p < 0.005), chemotherapy (p = 0.007), and hypertension (p = 0.002) as risk factors, and endocrine therapy (p = 0.001) and obesity (p = 0.024) as protective factors. MDPI 2023-05-29 /pmc/articles/PMC10253558/ /pubmed/37297941 http://dx.doi.org/10.3390/jcm12113747 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Ciobanu, George Adrian
Camen, Adrian
Ionescu, Mihaela
Vlad, Daniel
Munteanu, Cristina Maria
Gheorghiță, Mircea Ionuț
Lungulescu, Cristian Virgil
Staicu, Ionela Elisabeta
Sin, Elena Claudia
Chivu, Luminița
Mercuț, Răzvan
Popescu, Sanda Mihaela
Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid
title Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid
title_full Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid
title_fullStr Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid
title_full_unstemmed Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid
title_short Risk Factors for Medication-Related Osteonecrosis of the Jaw—A Binomial Analysis of Data of Cancer Patients from Craiova and Constanta Treated with Zoledronic Acid
title_sort risk factors for medication-related osteonecrosis of the jaw—a binomial analysis of data of cancer patients from craiova and constanta treated with zoledronic acid
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10253558/
https://www.ncbi.nlm.nih.gov/pubmed/37297941
http://dx.doi.org/10.3390/jcm12113747
work_keys_str_mv AT ciobanugeorgeadrian riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT camenadrian riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT ionescumihaela riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT vladdaniel riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT munteanucristinamaria riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT gheorghitamirceaionut riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT lungulescucristianvirgil riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT staicuionelaelisabeta riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT sinelenaclaudia riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT chivuluminita riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT mercutrazvan riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid
AT popescusandamihaela riskfactorsformedicationrelatedosteonecrosisofthejawabinomialanalysisofdataofcancerpatientsfromcraiovaandconstantatreatedwithzoledronicacid